A phase 1, randomized, single-blind, placebo-controlled study to assess the safety, pharmacokinetics, and pharmacodynamics of SD-101 in healthy normal male volunteers
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
At a glance
- Drugs SD 101 Dynavax (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Dynavax Technologies
- 26 Apr 2008 Status changed from recruiting to completed.
- 16 Feb 2008 New trial record.